INTRODUCTION
The Hedgehog (Hh) signaling pathway is a novel and potentially beneficial target for cancer therapy (Rubin and de Sauvage, 2006; Scales and de Sauvage, 2009) A role of aberrant Hh signaling in cancer was initially discovered in patients with Gorlin syndrome, a rare genetic disorder associated with predisposition to basal cell carcinoma (BCC), medulloblastoma, and rhabdomyosarcoma (Hahn et al., 1996; Johnson et al., 1996; Raffel et al., 1997; Epstein, 2008) . More recently, tumor-derived Hh ligand was found to activate the Hh pathway in adjacent tumor stroma (Yauch et al., 2008) .
Vismodegib (GDC-0449) is an orally bioavailable small molecule inhibitor of the Hh signaling pathway Von Hoff et al., 2009) . In a Phase I trial, vismodegib was well tolerated in patients with solid tumors and showed promising efficacy in advanced BCC . Vismodegib is currently undergoing evaluation in Phase II clinical trials and represents the most advanced of the Hh pathway inhibitors (HPIs) presently in clinical development (Scales and de Sauvage, 2009; Tremblay et al., 2009) .
In preclinical studies with vismodegib, the PK was favorable with low clearance in mouse, rat, and dog and moderate clearance in monkeys (Wong et al., 2009) . In vitro protein binding experiments indicated strong and reversible binding to both alpha-1-acid glycoprotein (AAG) and Human Serum Albumin (HSA), with approximately 10-fold greater affinity for AAG than HSA (Giannetti et al., 2011) . Blood-to-plasma partitioning of vismodegib in pooled human whole blood ranged from approximately 0.6 to 0.8 and was not concentration dependent (Wong et al., 2009 ). Vismodegib was highly stable but formed two primary oxidative metabolites M1 and M3, following in vitro incubations with human liver microsomes. These were principally formed by CYP3A4/5 and CYP2C9, respectively (Wong et al., 2009) . In a 14 C mass balance study in rats and dogs, vismodegib underwent extensive metabolism through oxidation of the 4-chloro-3-(pyridin-2-yl)-phenyl moiety followed by Phase II glucuronidation or sulfation. Further, three uncommon metabolites with pyridine ring opening (M9, M13 and M18) have been identified in rat or dog feces ( (Yue et al., 2011) ).
The pharmacokinetics (PK) of vismodegib was assessed in patients and healthy subjects. A half-life of approximately 10-14 days was reported following a single 150-mg oral dose administration to healthy volunteers (Ding et al., 2010) . Unique and non-linear properties were observed after continuous daily dosing in patients, and were explained by high-affinity plasma protein binding, nonlinear absorption, and slow metabolic elimination properties (Von Ding et al., 2010; Graham et al., 2011) . Vismodegib plasma concentration correlated strongly with alpha-1-acid glycoprotein (AAG) levels, showing parallel fluctuations of AAG and total drug over time (Giannetti et al., 2011; Graham et al., 2011) , suggesting protein binding plays a key role in the overall PK of vismodegib. During routine Phase I and Phase II drug development an exploratory analysis of human urine in patients receiving vismodegib, revealed only small amounts of parent drug and metabolites (data on file). Based on available preclinical data and the presence of minimal vismodegib in urine we hypothesized that the route of elimination of vismodegib is primarily hepatic, however, considering the high in vitro metabolic stability of vismodegib the relative contribution of metabolism and excretion of unchanged drug in humans remained to be determined.
To further understand the disposition of vismodegib, an open-label, Phase I, singlecenter AME study was conducted in healthy female volunteers of non-childbearing potential; this population was selected due to possible teratogenic effects of vismodegib. The Hh pathway plays a key role in embryogenesis (Ingham and McMahon, 2001 ) and cyclopamine, a naturally occurring inhibitor of SMO, has known teratogenic effects (Binns et al., 1972; Keeler, 1990) .
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This article has not been copyedited and formatted. The final version may differ from this version. The primary objective of the mass balance analysis was to determine the routes of excretion and extent of vismodegib metabolism following single oral dose administration. The secondary objective was to identify vismodegib metabolites in plasma, urine, and feces.
Based on the long half-life of vismodegib, we anticipated its low amount of excretion per day in urine/feces with less likelihood of sufficient recovery of the administered dose. It was observed that for long half-life drugs, the recovery of the dose in mass balance studies is historically low and at least in some cases, the cause is expected to be due to inadequate analytical sensitivity (Roffey et al., 2007) . For enhanced analytical sensitivity, we applied a tracer radiocarbon labeling approach that included assessment using the ultrasensitive analytical technology of accelerator mass spectrometry (AMS), providing detection of radioactivity over a long duration after administration of only tracer levels (Garner, 2000; Garner et al., 2000; Lappin and Garner, 2003; Beumer et al., 2007) . The use of AMS allowed for assessment of the excretion over a 56-day study period, the major part of this period was covered by intermitted sample collection intervals, which provided sufficient data to estimate the excretion of administered radioactivity. Here we report the results of a single dose human mass balance study with vismodegib, using AMS.
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Subject Selection
Females of non-child bearing potential between 18 and 65 years of age were enrolled at a study center in the Netherlands (PRA International, Zuidlaren, The Netherlands). The Clinical Study Protocol and its amendment, the Informed Consent Forms, and any information given to the subject and relevant supporting information were submitted for review and approval by the Independent Ethics Committee of the 'Stichting Beoordeling Ethiek Bio-Medisch Onderzoek'
(PO Box 1004, 9400 BA Assen, The Netherlands) prior to the eligibility screening. All participants were informed verbally and in writing regarding the objectives, procedures, and risks of study participation. All subjects signed the ethics committee-approved study consent form during the pre-study screening visit before any study related procedures were started.
Participants were excluded if any of the following criteria were applicable: history of stomach or intestinal surgery, stomach disease, or resection that would potentially alter absorption and/or excretion of orally administered drugs; irregular defecation pattern or acute constipation problems within 3 weeks prior to Day 1; use of any prescription medications/products, including known enzyme-inducing/inhibiting agents, over-the-counter medication, or other nonprescription preparations within 2 weeks prior to Day 1; smoking, use of tobacco, or nicotinecontaining/nicotine-replacement products for ≥ 6 months before start of study. The study was conducted in accordance with the principles of the Declaration of Helsinki including
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Excluded and Concomitant Therapies
While on-study, subjects could not take prescription medications/products, over-thecounter medication, any known enzyme-inducing/inhibiting agents (e.g., rifampin, St. John's wort, or other hypericum perforatum−containing substance, ketoconazole, etc.), investigational drugs, or other non-prescription preparations, with the exception of hormone-replacement therapy. Subjects could not receive vaccinations or blood products. Subjects could not take nicotine-containing or nicotine-replacement products, alcohol or methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, "powerdrinks") until Day 14; after day 14, these substances were not permitted within 24 h before a study visit, unless deemed acceptable by the Medical Investigator. In addition, subjects were advised not to engage in strenuous activity until completion of the study.
Study Design and Data Collection
Six healthy female subjects meeting study entry criteria, were dosed with vismodegib.
All subjects arrived for admission to the clinical research facility in the afternoon preceding the day of drug administration. Upon admission to the clinical research facility, the inclusion and exclusion criteria were re-checked and the drug screen (including alcohol) was repeated. The occurrence of baseline complaints or adverse events (AEs) and the use of concomitant medication were checked and recorded.
On Day 1, subjects received a 30-mL oral suspension containing 150 mg of vismodegib with 6.5 μg of 14 C-vismodegib to give a radioactivity of approximately 37 kBq (1000 nCi). After the suspension was administered the container was rinsed 3 times with approximately 50 mL of
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The solution, including the rinse, was consumed within 5 minutes. Serial pharmacokinetic blood, urine, and feces samples for vismodegib (plasma) and total radioactivity (whole blood, plasma, urine, and feces) analysis, were collected at pre-determined times after the single oral dose administration, up to 312 h (Day 14) during which time the subjects were confined to the clinical research facility (Figure 2 ). Subjects also checked into the clinic for 24-h overnight visits on Days 21, 28, 35, 42, 49, and 56 (± 1 day). During these visits, blood samples for PK as well as total radioactivity analysis and all urine and feces for total radioactivity analysis, were collected. Subjects were instructed to start feces collection 24 h before checking in for the overnight visits (i.e., on Days 20, 27, 34, 41, 48, and 55 (± 1 day)) and to continue collection at home until the next visit, if no feces was produced in the targeted 48-h period. The study completion visit took place on Day 56 (± 1 day).
Safety data for all subjects who had received any amount of vismodegib were analyzed in the safety analyses. Safety was assessed by summaries of adverse events (AEs), changes in laboratory test results, vital signs, ECG and physical examination findings.
Bioanalytical Methods

Radioanalysis:
14 C-radioanalysis in whole blood, plasma, urine, and feces was performed using AMS by Xceleron (Xceleron, York, UK). Whole blood (20 µL), undiluted plasma (60 µL), pooled plasma samples (60 µL), diluted urine (100 µL) and freeze-dried feces (~4 mg) were placed in sample tubes containing pre-baked copper oxide wire (50±10 mg).
Briefly, sample pretreatment consisted of the conversion of the carbon within the samples to graphite via a two-step process of oxidation and reduction (Vogel, 1992; Lappin and Garner, 2004) . Each sample was counted in the AMS instrument for a minimum of 100 s, and this was repeated for each sample at least three times. AMS data were converted to either disintegrations per minute (dpm) either per milliliter or per gram taking into account the carbon
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Bioanalysis of unlabelled vismodegib:
Non-radiolabelled vismodegib plasma concentrations were determined by Tandem Labs (Salt Lake City, UT) using a validated solid phase extraction LC-MS/MS method, using reverse-phase chromatography coupled with a TurboIonSpray TM interface validated over a calibration curve range of 5 to 5000 ng/mL (0.012-11.9 µM) (Ding et al., 2010) .
Metabolite Profiling Analysis
Sample preparation: Plasma was pooled (by equal volumes) across all subjects at selected time points (i.e., 4, 24, 168, and 312 h) and spiked with a solution containing vismodegib (4.1 mg/mL) as a chromatographic marker. Pooled plasma (500 µL) and acetonitrile (ACN) (1500 µL) were combined, vortex-mixed and sonicated (15 minutes) followed by centrifugation at 2095 x g for 10 minutes at +4ºC. The supernatant layer was removed and the
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This article has not been copyedited and formatted. The final version may differ from this version. pellet re-extracted two additional times with ACN (1500 µL). The supernatants were pooled and evaporated to complete dryness under a stream of nitrogen gas. The extract was reconstituted with methanol followed by 0.1% formic acid (FA).
Homogenized feces samples were pooled (by equivalent percent weight) across all subjects for selected time periods (0-72 h and 72-312 h) and spiked with a solution containing non-radiolabeled vismodegib and prepared as described above, however the matrix:solvent ratio differed slightly (~1g feces homogenate was extracted with 2 mL ACN). Urine samples were pooled (by equivalent percent volume) across all subjects for the selected time period (0-312 h) and the pooled sample was spiked with a solution containing non-radiolabeled vismodegib prior to direct injection onto the HPLC system. Aliquots of extracted samples were analyzed by AMS to determine extraction recovery of total radioactivity (ie all vismodegibrelated material). (2.5 µL; equivalent to ca 2 mg carbon) and pre-baked copper oxide wire (50±10 mg), dried under vacuum, then converted to graphite as described above.
HPLC column recoveries were determined for selected samples by collecting the total HPLC column eluate for the appropriate run as a single sample and assaying the radioactivity content using AMS.
Structure Identification of Metabolites
The same pooled plasma (4, 24, 168 and 312 h), urine (0-312 h), and feces (0-72 and 72-312 h) samples as used for metabolite profiling analysis were selected for metabolite identification. This was performed on an Accela HPLC system with a built-in degasser and autosampler coupled with a high resolution mass spectrometer LTQ-Orbitrap from Thermo
Fisher Scientific, Inc. (San Jose, CA). The HPLC conditions were the same as described above for metabolite profiling. The LTQ-Orbitrap mass spectrometer was equipped with a Max-ESI source and operated in the positive electrospray ionization (ESI) mode. The electrospray ion source voltage was 4.5 kV. The heated capillary temperature was 350°C. Auxiliary and sheath gases were set to 10 and 25 units, respectively. The scan-event cycle consisted of a full-scan mass spectrum at a resolving power of 30,000 (at m/z 400) and the corresponding data-dependent tandem mass spectrometry (MS n ) scans acquired at a resolving power of 7500.
Accurate mass measurements were performed using external calibration.
A 5500 QTRAP ® linear ion trap mass spectrometer (AB SCIEX, Foster City, CA) equipped with a TurboIonSpray source and a Shimadzu ® LC-20AD HPLC System (Shimadzu Scientific Instruments, Columbia, MD) was also used to obtain enhanced product ion mass spectra for the metabolites of interest. The LC column, mobile phases, and gradient were the same as described as above. Precursor information-dependent acquisition (IDA), multiple
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This article has not been copyedited and formatted. The final version may differ from this version. Metabolites were identified on the basis of accurate masses of protonated molecular ions and their collision-induced dissociation (CID) fragmentation. Authentic standards, when available, were used to compare chromatographic retention times and fragmentation patterns.
The same metabolites identified in rat and dog radiolabeled bile and feces samples and in samples of vismodegib incubated with CYP3A4 and CYP2C9 recombinant enzymes were compared in the assignment of metabolite structures (Yue et al., 2011) ).
Pharmacokinetic Analysis
Individual and mean plasma concentration-time data were plotted. PK parameters were calculated using a non-compartmental model with WinNonlin ® (Pharsight Corporation, version
5.2.1, Mountain View, CA). Plasma concentration values in ng or ng equivalents per mL were
converted to µM using the molecular weight of vismodegib (421.3 g/mol). All area under the concentration-time curve (AUC) values were calculated using the linear trapezoidal method when the concentrations were rising and by the logarithmic trapezoidal method when the concentrations were declining (Linear up/log down rule in WinNonlin ® ). Below the limit of quantitation (BLQ) values at pre-dose were considered as zero for PK analysis. Actual blood collection time was used to calculate PK parameters and the parameters were summarized by mean and standard deviation (SD). Total radioactivity measured by AMS was converted to dpm/mL. Specific activity of the administered dose was determined from the specific activity of 14 C-vismodegib reference standard and the amount of non-labeled vismodegib added to make up the dose suspension. The specific activity of the administered dose was used to calculate the drug concentration in plasma in ng equivalents per mL.
Cumulative excretion was expressed as a percent of the administered dose and was determined in urine and feces over the study duration. Cumulative recovery was calculated as
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RESULTS
Subject Disposition
All 6 subjects completed the study with no reported adverse events that were greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or that were considered to be related to vismodegib.
Plasma Pharmacokinetics
Plasma concentration-time curves for unlabeled vismodegib (LC-MS/MS) and total radioactivity (AMS) are shown in Figure 3 . Following a single dose of an oral suspension, nonradiolabelled vismodegib and total radioactivity appeared to be absorbed over two days followed by a very slow terminal elimination phase with mean half-life values of 9.33 and 9.46 days, respectively. Plasma levels of unlabelled vismodegib and total radioactivity were detected over the entire 56-day study period. On average, C max and AUC (0-inf) for total radioactivity were higher than for unlabeled vismodegib (1.51-fold and 1.35-fold, respectively), however the elimination half-lives (t 1/2 ) were similar for both analytes (Table 1 ). The AUC ratio of unlabeled vismodegib to total radioactivity was variable, ranging from 0.469 to 0.949. Over the 56-day plasma sampling period, AUC and terminal elimination rate constant were adequately determined despite the long t 1/2 with the extrapolated AUC represented by only 3.2% and 3.6% of the AUC 0-inf (total radioactivity and unlabeled vismodegib, respectively).
Blood to Plasma Partitioning
Blood to plasma partitioning was evaluated at 4, 24, 144, and 312 h after vismodegib administration. In general, the blood to plasma partition ratio was similar at each sampling time and the mean values (by sampling time) ranged from 0.687 to 0.709 (data on file); a result that is consistent with preclinical studies using human pooled whole blood (Wong et al., 2009 ).
Mass Balance
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This article has not been copyedited and formatted. The final version may differ from this version. As shown in Figure 4 , approximately 50% of the administered dose was recovered in feces by 7-days post dose with the remainder recovered through the end of the study. All subjects provided at least one feces sample during all collection intervals; either from at home feces collections or during the overnight clinic visits, or both. Urinary recovery was consistently low throughout the study. During the 56 day collection period the estimated average recovery of vismodegib -related radioactivity was 86.6% (range, 72.7% to 95.0%) of the administered dose with 82.2% (67.2% to 91.9%) recovered in feces. Recovery of radioactivity in urine was a relatively low 4.43% (range, 2.89 to 6.03%) ( Table 2 ). The estimated total excretion of the administered dose was greater than or equal to 84.7% in five of the six subjects. Drug-related total radioactivity was still detectable in plasma on Day 56 for all subjects.
Metabolite Profile and Identification
Plasma: The mean extraction recovery of total radioactivity from human plasma was 84.3% (83.5% at 4h, 94.6% at 24h, 83.4% at 168h and 75.8% at 312 h). A representative plasma radiochromatogram obtained from AMS analysis is presented in Figure 5A . The HPLC column recovery was greater than 95.9% for all selected samples. Vismodegib was predominant (> 98% of the total radioactivity) in human plasma at all time intervals (4, 24, 168, and 312 h). This result was confirmed by profiling plasma from subject S0012, the subject with the lowest AUC ratio of unlabeled vismodegib to total radioactivity (Supplementary Figure 1) .
Trace levels of oxidative metabolite M3 and glucuronides M4 and M5 were detected in 4 h post dose plasma by high-resolution MS only; notably similar results were obtained in the 24, 168
and 312 h post-dose plasma samples. Proposed structures and supporting spectra data are presented in Figure 6 and Table 3 , respectively.
Urine: While no significant radioactive peaks were observed by AMS analysis, based on high-resolution MS and MS/MS, minor oxidative metabolites M1, M3, and M14; glucuronides
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Feces:
The distribution of metabolites detected in feces is listed in Table 4 and HPLC radiochromatographic profiles of pooled feces are presented in Figures 5B and 5C . The mean extraction recovery of fecal radioactivity was 84.7% (83.7% to 87.6% at 0-72 h and 72-312 h post dose, respectively). In feces over 0-72 h post-dose, vismodegib was dominant, representing 21.7% of the dose while only one metabolite (M3) was detected by AMS representing 3.2% of the dose ( Figure 5B ). Over 72-312 h post-dose, vismodegib was 9.0% of the dose in feces and additional metabolites were detected during this period ( Figure 5C ).
Metabolites M1, M3, M13, and M18 represented 1.1% 12.0%, 3.0%, and 2.0% of the dose in human feces, respectively.
While the results from pooled feces samples collected at 0-72 h and 72-312 h intervals described above were informative, it was difficult to discern between unabsorbed vismodegib and excreted radioactivity of absorbed vismodegib (i.e., unchanged vismodegib or metabolites).
To this end, additional feces samples were pooled across all subjects over 24 h intervals postdose through 312 h (Table 5) . Over the first 72 h post-dose, most of the total radioactivity was associated with vismodegib with up to 5% represented by M3. In the 72-96 h collection interval, the vismodegib contribution to total radioactivity in feces had decreased considerably and approximately 10% of the total radioactivity was from M3. From 96-120 h through the 288-312 h collection interval, the majority of the total radioactivity was represented by components other than vismodegib and M3.
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DISCUSSION
The primary aim of the present study was to determine the disposition and excretion of vismodegib, however given the long single dose half-life, the study design posed challenges different from those of traditional human mass balance studies. We considered a traditional mass balance approach for vismodegib, however this would have required high levels of radioactivity (relative to AMS) to be administered to healthy subjects with the radioactivity persisting in plasma for a long duration (due to the long half life) with inherent concerns for cumulative radioactive exposure. Furthermore, we expected a small fraction of radioactivity to be excreted per day in amounts that would be insufficient for detection by conventional means.
Thus, there would be a low likelihood of sufficient recovery of the administered dose, particularly at later timepoints. Therefore, we proposed to utilize AMS to maximize the probability of technical success for the present study (i.e., obtaining an acceptable recovery of the administered dose) with the added benefit of minimzing the exposure of subjects to radioactivity over the long study duration.
Following administration of 14 C-vismodegib oral suspension the average total estimated excretion was >85% of the administered dose over a collection period of 56 days, with the majority of vismodegib -related radioactivity recovered in feces and low recovery in urine.
Notably, detectable drug-related material remained in plasma, urine and feces in all subjects on Day 56, which suggests that recovery could have been even more complete if urine and feces collections would have continued beyond Day 56. The lack of more complete recovery is likely due to inadequate study duration, losses via other routes than urine and feces (notably perspiration), weekly collection intervals, and/or the excretion estimation method necessitated by the long half-life of vismodegib.
The PK parameters of vismodegib in the present study were generally similar to those reported previously in healthy volunteers following a 150 mg oral dose despite differences in the formulations (oral suspension versus solid capsule ) (Ding et al., 2010) . Single dose and
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This article has not been copyedited and formatted. The final version may differ from this version. multiple dose IV and oral pharmacokinetics in healthy volunteers administered the to-bemarketed formulation, will be reported in a separate publication. Herein we reported only those PK measures that are relevant to the mass balance study, including the AUC ratio for plasma vismodegib to total radioactivity.
Profiling results showed that unchanged vismodegib was predominant in plasma, corresponding to greater than 98% of the total circulating radioactivity at 4, 24, 168, and 312 h.
The average AUC ratio for unlabeled vismodegib (corrected for extraction efficiency) and total radioactivity in plasma was 0.757, which is not entirely consistent with the plasma profiling results. In other words, the AUC ratio was expected to be closer to 1, on average. This was in fact the case for 3 of 6 subjects (S0007, S0008 and S0010), with AUC ratios of 0.878, 0.988, and 0.898, respectively; however AUC ratios were much lower for S0009, S0011 and S0012 (0.637, 0.671, and 0.468, respectively) . Inspection of the individual concentration versus time profiles suggests that the lower AUC ratio for these three subjects was propagated from lower unlabeled vismodegib plasma concentrations over the entire time course and not in a particular phase of the profile. An issue with comparing AUC ratios in this study is that two different bioanalytical techniques (AMS and LC-MS/MS), each with their own inherent measurement error, could be expected to give rise to variability in this parameter. Nonetheless, the inconsistency between AUC ratio and plasma profiling results has no impact on the overall interpretation of the study results because the primary route of elimination and extent of metabolism were clear from the totality of the data.
Seven minor metabolites were identified from human pooled plasma, urine and feces, including oxidative metabolites (M1, M3, and M14), glucuronides (M4 and M5) and pyridine ring cleavage metabolites (M13 and M18). The structures of the metabolites were characterized by high resolution MS and CID spectra with mass accuracy better than 1 ppm. The HPLC retention time and mass spectra of human metabolites confirmed that these metabolites matched those present in preclinical species. All metabolites identified were consistent with
This article has not been copyedited and formatted. The final version may differ from this version. those observed in rat and dog mass balance studies (Yue et al., 2011) . Of note, two uncommon pyridine ring opening metabolites M13 and M18, which represented 5% of the dose in total in human feces (also observed in rats and dogs) were absent from in vitro hepatic incubations (Yue et al., 2011) . These observations may be explained by either very slow hepatic turnover of vismodegib observed in microsomes and hepatocytes or the involvement of extra-hepatic enzymes in their formation. Further investigations are underway to study the mechanism of M13 and M18 formation.
Vismodegib was slowly eliminated by a combination of extensive metabolism and excretion of parent drug, the majority of which was recovered in feces. Over the first three days after dose administration, the majority of the recovered radioactivity in feces likely represented unabsorbed vismodegib. However, a substantial portion of the estimated excreted radioactivity in feces was recovered in the period following the first 3 days. From Day 6 through Day 14, less than 15% (on average) of the total radioactivity per day recovered in feces was attributed to parent vismodegib suggesting that after GI transit (2-3 days) (Davies and Morris, 1993) , the recovered radioactivity in feces likely represents drug that had been absorbed and excreted unchanged or as metabolites.
In summary, vismodegib was absorbed and slowly eliminated as a combination of the unchanged parent form and its metabolites after oral dosing in healthy volunteers. The majority of the administered radioactivity was recovered in feces indicating hepatic elimination predominates for vismodegib.
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